Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022* Since the interview, NeuroSense successfully concluded  additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by the end of 2022 and present Top Line results by Q2 2023. The company is traded on Nasdaq under the ticker NRSN. Summary of  interview: 01:13    Tell us about your career journey and meeting Shay Rishoni 06:25    Tell us about ALS and why it has become a relatively well-known orphan indication 09:30    Tell us about PrimceC 12:40    Could you talk about your financing journey 16:13     Did the crowdfunding process affect your public offering in some sort of way?  18:54    Is it true that zebrafish have over 70% genetic similarity to humans? How is that even possible? 21:00     Could you expand on the leadership team at NeuroSense?  23:10    How has your personal life changed since the company was floated to NASDAQ? 25:00   You have a very unique organizational culture in NeuroSense Therapeutics and you're growing.  How do you intend to keep some of that culture while you grow?  27:30     What’s next forNeuroSense? What are the next milestones and pipeline products? 30:15    How long do you expect you are away from the market with the PrimeC? 31:05  Have you put any thoughts to having a companion diagnostic? 32:25   What are your thoughts about the Israeli ecosystem? 34:25   If you could go back to your 16-year-old self and tell yourself something, what do you think it would be? 35:40  Are there any  people in your journey that were meaningful to you personally and to NeuroSense Therapeutics